P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 12.73 CNY 0.16% Market Closed
Market Cap: 4.4B CNY

Pulike Biological Engineering Inc
Additional Paid In Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Pulike Biological Engineering Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
P
Pulike Biological Engineering Inc
SSE:603566
Additional Paid In Capital
ÂĄ1.2B
CAGR 3-Years
-3%
CAGR 5-Years
22%
CAGR 10-Years
8%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Additional Paid In Capital
ÂĄ1.1B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
3%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Additional Paid In Capital
ÂĄ12.9B
CAGR 3-Years
68%
CAGR 5-Years
48%
CAGR 10-Years
41%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Additional Paid In Capital
ÂĄ17.7B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
30%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Additional Paid In Capital
ÂĄ886m
CAGR 3-Years
297%
CAGR 5-Years
28%
CAGR 10-Years
N/A
No Stocks Found

Pulike Biological Engineering Inc
Glance View

Market Cap
4.4B CNY
Industry
Pharmaceuticals

Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Intrinsic Value
17.37 CNY
Undervaluation 27%
Intrinsic Value
Price
P

See Also

What is Pulike Biological Engineering Inc's Additional Paid In Capital?
Additional Paid In Capital
1.2B CNY

Based on the financial report for Sep 30, 2025, Pulike Biological Engineering Inc's Additional Paid In Capital amounts to 1.2B CNY.

What is Pulike Biological Engineering Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
8%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Pulike Biological Engineering Inc have been -3% over the past three years , 22% over the past five years , and 8% over the past ten years .

Back to Top